TRPC Channels and Their Splice Variants are Essential for Promoting Human Ovarian Cancer Cell Proliferation and Tumorigenesis

Zeng, Bo; Yuan, Cunzhong; Yang, Xingsheng; Atkin, Stephen L.; Xu, Shang-Zhong

Abstract

TRPC channels are Ca2+-permeable cationic channels controlling Ca2+ influx response to the activation of G protein-coupled receptors and protein tyrosine kinase pathways or the depletion of Ca2+ stores. Here we aimed to investigate whether TRPC can act as the potential therapeutic targets for ovarian cancer. The mRNAs of TRPC1, TRPC3, TRPC4 and TRPC6 were detected in human ovarian adenocarcinoma. The spliced variants of TRPC1β, TRPC3a, TRPC4β, TRPC4γ, and TRPC6 with exon 3 and 4 deletion were highly expressed in the ovarian cancer cells, and a novel spliced isoform of TRPC1 with exon 9 deletion (TRPC1E9del) was identified. TRPC proteins were also detected by Western blotting and immunostaining. The expression of TRPC1, TRPC3, TRPC4 and TRPC6 was significantly lower in the undifferentiated ovarian cancer cells, but all-trans retinoic acid up-regulated the gene expression of TRPCs. The expression level was correlated to the cancer differentiation grade. The non-selective TRPC channel blockers, 2-APB and SKF-96365, significantly inhibited the cell proliferation, whilst the increase of TRPC channel activity by trypsin promoted the cell proliferation. Transfection with siRNA targeting TRPC1, TRPC3, TRPC4 and TRPC6 or application of specific blocking antibodies targeting to TRPC channels inhibited the cell proliferation. On the contrary, overexpression of TRPC1, TRPC1E9del, TRPC3, TRPC4, and TRPC6 increased the cancer cell colony growth. These results suggest that TRPCs and their spliced variants are important for human ovarian cancer development and alteration of the expression or activity of these channels could be a new strategy for anticancer therapy.

Citation

Zeng, B., Yuan, C., Yang, X., Atkin, S. L., & Xu, S.-Z. (2013). TRPC Channels and Their Splice Variants are Essential for Promoting Human Ovarian Cancer Cell Proliferation and Tumorigenesis. Current Cancer Drug Targets, 13(1), 103-116. https://doi.org/10.2174/156800913804486629

• Journal Article Type: Article
• Publication Date: Jan 1, 2013
• Deposit Date: Jun 8, 2022
• Publicly Available Date: Jul 10, 2024
• Journal: Current Cancer Drug Targets
• Print ISSN: 1568-0096
• Publisher: Bentham Science Publishers
• Peer Reviewed: Peer Reviewed
• Volume: 13
• Issue: 1
• Pages: 103-116
• DOI: https://doi.org/10.2174/156800913804486629
• Public URL: https://hull-repository.worktribe.com/output/3741837